EP2398322A4 - Estrogen receptor ligands and methods of use thereof - Google Patents

Estrogen receptor ligands and methods of use thereof

Info

Publication number
EP2398322A4
EP2398322A4 EP10744458A EP10744458A EP2398322A4 EP 2398322 A4 EP2398322 A4 EP 2398322A4 EP 10744458 A EP10744458 A EP 10744458A EP 10744458 A EP10744458 A EP 10744458A EP 2398322 A4 EP2398322 A4 EP 2398322A4
Authority
EP
European Patent Office
Prior art keywords
methods
estrogen receptor
receptor ligands
ligands
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10744458A
Other languages
German (de)
French (fr)
Other versions
EP2398322A1 (en
Inventor
James T Dalton
Mitchell S Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of EP2398322A1 publication Critical patent/EP2398322A1/en
Publication of EP2398322A4 publication Critical patent/EP2398322A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
EP10744458A 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof Withdrawn EP2398322A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15470709P 2009-02-23 2009-02-23
US16898309P 2009-04-14 2009-04-14
US26166909P 2009-11-16 2009-11-16
PCT/US2010/025032 WO2010096801A1 (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof

Publications (2)

Publication Number Publication Date
EP2398322A1 EP2398322A1 (en) 2011-12-28
EP2398322A4 true EP2398322A4 (en) 2012-12-05

Family

ID=42634248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10744458A Withdrawn EP2398322A4 (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof

Country Status (10)

Country Link
EP (1) EP2398322A4 (en)
JP (1) JP5611991B2 (en)
KR (3) KR20130101146A (en)
CN (1) CN102413692B (en)
BR (1) BR112014004008A2 (en)
CA (1) CA2753436C (en)
IL (1) IL214805A0 (en)
MX (1) MX340753B (en)
RU (1) RU2543339C2 (en)
WO (1) WO2010096801A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8680055B2 (en) 2009-06-03 2014-03-25 University Of Southern California Methods for decreasing steroidogenesis in prostate cancer cells
JP2014524479A (en) * 2011-08-23 2014-09-22 ジーティーエックス・インコーポレイテッド Estrogen receptor ligands and methods of use thereof
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014039820A1 (en) * 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062230A2 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
US20100267773A1 (en) * 2005-11-28 2010-10-21 Dalton James T Estrogen receptor ligands and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062230A2 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
US20100267773A1 (en) * 2005-11-28 2010-10-21 Dalton James T Estrogen receptor ligands and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HO SHUK-MEI: "Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates", JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 91, 1 January 2004 (2004-01-01), pages 491 - 503, XP002982229, ISSN: 0730-2312, DOI: 10.1002/JCB.10759 *
See also references of WO2010096801A1 *

Also Published As

Publication number Publication date
CN102413692B (en) 2015-01-07
MX340753B (en) 2016-07-25
CN102413692A (en) 2012-04-11
JP2012518654A (en) 2012-08-16
BR112014004008A2 (en) 2017-03-28
AU2010215809A1 (en) 2011-09-22
KR20110131227A (en) 2011-12-06
CA2753436A1 (en) 2010-08-26
CA2753436C (en) 2016-05-24
KR20150135547A (en) 2015-12-02
KR101458539B1 (en) 2014-11-10
WO2010096801A1 (en) 2010-08-26
EP2398322A1 (en) 2011-12-28
RU2011137324A (en) 2013-03-27
RU2543339C2 (en) 2015-02-27
JP5611991B2 (en) 2014-10-22
IL214805A0 (en) 2011-11-30
KR20130101146A (en) 2013-09-12
MX2011008879A (en) 2012-04-30

Similar Documents

Publication Publication Date Title
IL250624B (en) Anti-fgfr3 antibodies and methods using same
GB2483736B (en) Estrogen receptor modulators and uses thereof
EP2427479A4 (en) Antibodies and methods of use thereof
ZA201105791B (en) New adenosine receptor ligands and uses thereof
IL214805A0 (en) Estrogen receptor ligands and methods of use thereof
ZA201208603B (en) Estrogen receptor modulators and uses thereof
IL215795A0 (en) Anti-il-17f antibodies and methods of use thereof
EP2543008A4 (en) Methods and apparatuses for facilitating location selection
EP2464227A4 (en) Compounds and methods of use thereof
EP2538780A4 (en) Estrogen receptor ligands and methods of use thereof
IL219136A0 (en) Anti-hepsin antibodies and methods using same
EP2406244A4 (en) Estrogenic compounds and their methods of use
EP2419561A4 (en) Coated fabric and related methods therefor
GB2467764B (en) Attachment means and methods
IL231070A0 (en) Estrogen receptor and methods of use thereof
GB201011673D0 (en) Up and down bowl
HK1174620A1 (en) Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1159422

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20121106

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/40 20060101AFI20121030BHEP

Ipc: A61K 31/55 20060101ALI20121030BHEP

Ipc: A61K 31/445 20060101ALI20121030BHEP

17Q First examination report despatched

Effective date: 20130705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161112

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1159422

Country of ref document: HK